Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma
NCT02548195Phase 3Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2015
- Primary completion
- Jun 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of gemcitabine, oxaliplatin in intrahepatic cholangiocarcinoma (ICC), sponsored by Zhongshan Hospital, Fudan University. Status: unknown.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT02548195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02548195.